Whitehawk Therapeutics (WHWK) Debt Ratio (2020 - 2021)
Whitehawk Therapeutics (WHWK) posted quarterly Debt Ratio of 0.04 for Q4 2021, down 94.99% year-over-year from 0.76 in Q4 2020, and up 11.24% quarter-over-quarter from 0.03 in Q3 2021.
Whitehawk Therapeutics (WHWK) Debt Ratio (2020 - 2021) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Debt Ratio for 2 consecutive years, with 0.04 the latest figure, recorded in Q4 2021.
- In Q4 2021, Debt Ratio fell 94.99% year-over-year to 0.04; the TTM figure through Dec 2021 stood at 0.04 (down 94.99% YoY), while the FY2021 annual figure was 0.04, down 94.99% from the prior year.
- Debt Ratio advanced to 0.04 in Q4 2021 per WHWK's latest filing, from 0.03 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.76 in Q4 2020 and bottomed at 0.03 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.12 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.47 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.26 |
| 10 | Whitehawk Therapeutics | 369.67 Mn | 74.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 0.04 |
| Sep 30, 2021 | 0.03 |
| Dec 31, 2020 | 0.76 |